Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MetaStat, Inc. (OTC: MTST).

Full DD Report for MTST

You must become a subscriber to view this report.


Recent News from (OTC: MTST)

MetaStat voluntarily withdraws listing on the OTCQB
MetaStat ( OTCPK:MTST -44.4% ) voluntarily withdraws listing on the OTCQB & files form 15 to suspend its reporting obligations. More news on: MetaStat, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: July, 17 2018 12:25
MetaStat Voluntarily Withdraws Listing on the OTCQB and Files Form 15 to Suspend its Reporting Obligations
MetaStat, Inc. (OTCQB:MTST) (the “Company”), a precision medicine company developing novel anti-metastatic drugs for the treatment of patients with aggressive cancer, today announced the Company is voluntarily deregistering its common stock under Section 12(g) of the Securities...
Source: Business Wire
Date: July, 16 2018 16:05
MetaStat Presents Positive Data Showing Inhibition of the MENA-pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer
Data presented at the AACR Cancer Dormancy and Residual Disease meeting support a novel therapeutic approach to combating the spread of aggressive cancer MetaStat, Inc. (OTCQB: MTST), a precision medicine company developing novel anti-metastatic medications for patients with aggressiv...
Source: Business Wire
Date: June, 21 2018 07:30
MetaStat Announces Positive Topline Data Showing Over 50% Reduction in Cancer Metastasis from Preclinical Studies Evaluating Inhibition of the MAPKAPK2 Kinase Pathway
Successful Completion of the Pilot Research Project with Celgene Corporation. MetaStat, Inc. (OTCQB: MTST), a precision medicine company developing novel anti-metastatic treatment solutions for patients with aggressive cancer, announced today positive results and the successful comple...
Source: Business Wire
Date: February, 28 2018 07:30
MetaStat Announces Upcoming Investor and Pharmaceutical Industry Partnering Conference Presentations
MetaStat, Inc. (OTCQB:MTST), a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients, announced today that its CEO Douglas A. Hamilton will present at the following Investor and Pharmaceutical Industry Partnering Conferences. ...
Source: Business Wire
Date: September, 25 2017 12:52

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-14N/A0.10N/AN/A0
2018-12-13N/A0.10N/AN/A0
2018-12-12N/A0.10N/AN/A66
2018-12-11N/A0.10N/AN/A0
2018-12-10N/A0.10N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-135,00010,13349.3437Short
2018-11-095,00040,00012.5000Cover
2018-10-3015,00043,00034.8837Cover
2018-07-2711,00011,00199.9909Short
2018-07-235,0005,20096.1538Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MTST.


About MetaStat, Inc. (OTC: MTST)

Logo for MetaStat, Inc. (OTC: MTST)

MetaStat is a precision medicine company dedicated to transforming the treatment of patients with aggressive cancer. Our mission is to evolve cancer treatment into a manageable disease through targeted therapies that arrest cancer cell dissemination and metastatic progression. Aggressive cancer that spreads or metastasizes to other parts of the body is responsible for approximately of cancer related deaths, yet there are no anti metastatic drugs on the market. MetaStat s drug discovery program is focused on developing novel drug candidates that target the Mena dependent metastatic cascade. MetaStat is developing novel small molecule and peptide based kinase inhibitors that target the MAPKAPK pathway responsible for activation of Mena. The company s Mena CDx companion diagnostic assay identifies patients with Mena high tumors at risk for cancer metastasis and most likely to benefit from anti Mena therapy. MetaStat is based in Boston, MA.

 

Contact Information

 

 

Current Management

  • Douglas A. Hamilton / CEO, President
  • Daniel Schneiderman / VP, Fin., Secretary
  • Jerome B. Zeldis / Chairman, Independent Director
  • Paul Billings / Independent Director
  • Douglas A. Hamilton /

Current Share Structure

  • Market Cap: $4,701,906 - 03/15/2018
  • Authorized: 150,000,000 - 02/28/2018
  • Issue and Outstanding: 5,877,383 - 02/28/2018
  • Float: 1,941,520 - 02/28/2018

 


Recent Filings from (OTC: MTST)

Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: April, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: January, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 02 2017
Filing Type: CT ORDERFiling Source: edgar
Filing Date: October, 19 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: October, 16 2017
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: October, 05 2017

 

 


Daily Technical Chart for (OTC: MTST)

Daily Technical Chart for (OTC: MTST)


Stay tuned for daily updates and more on (OTC: MTST)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MTST)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MTST is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MTST and does not buy, sell, or trade any shares of MTST. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/